NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer.

Yuan YuanHuanyao GaoYongxian ZhuangLixuan WeiJia YuZhe ZhangLili ZhangLiewei Wang

Published in: Therapeutic advances in medical oncology (2021)

We identified NDUFA4L2 as a new biomarker and potential therapeutic target for TR HER2-positive breast cancer.

Keyphrases